查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1887995

全球抗體發現市場：按提供、技術、抗體類型、治療領域、性質、最終用戶和國家分類的分析和預測（2025-2035年）

Antibody Discovery Market - A Global and Regional Analysis: Focus on Offering, Technology, Antibody Type, Therapeutics, Nature, End User, and Country - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 196 Pages | 商品交期: 1-5個工作天內

價格

全球抗體發現市場預計將從2025年的約 111.5億美元成長到2035年的353.5億美元，年複合成長率約為 12.23%。

全球抗體發現市場正經歷快速發展，工程技術、自動化和人工智慧的進步是推動該成長的關鍵趨勢之一。全人源和人源化抗體的研發正日益普及，它們能夠提高治療安全性、特異性和療效，同時降低免疫抗原性。在噬菌體展示、基因改造動物模型和糖基化工程等技術的支持下，這些抗體研發模式革新癌症、自體免疫疾病和感染疾病的治療方式。此外，高通量篩檢、次世代定序和自動化技術的整合簡化抗體鑑定和最佳化流程，顯著縮短研發週期並提高成本效益。對合約研究組織（CRO）日益成長的依賴，為抗體篩檢和工程改造提供了專業的基礎設施和專業知識，進一步提升了擴充性並加速了創新。

關鍵市場統計資料
預測期 2025-2035
2025年評估 111.5億美元
2035年預測 353.5億美元
年複合成長率 12.23%

此外，人工智慧和機器學習透過實現預測建模、親和性最佳化和快速序列設計，變革藥物發現流程。這些工具提高了準確性並降低了研發成本，滿足了日益成長的精準醫療需求。雙特異性抗體、抗體藥物複合體和單域抗體等創新技術擴展腫瘤學、免疫學和罕見疾病領域的治療可能性。儘管面臨高昂的生產成本以及來自基因療法和細胞療法等替代療法的競爭等挑戰，但自動化、生物資訊學和流程擴充性的持續進步預計將在未來十年推動全球抗體發現市場的持續成長和技術成熟。

細分 1：依服務類別

以產品細分來看，產品細分佔了較大的佔有率，其中包括發現工作流程中不可或缺、高價值和經常性消費的產品，例如抗體發現平台和系統、試劑盒、試劑、抗體庫等。服務也能帶來可觀的收入，但產品銷售通常嵌入多個計劃中，形成更廣泛的收入基礎。

細分2：依技術

從技術角度來看，噬菌體展示技術在抗體發現市場中佔據主導地位，因為它能夠對大規模的抗體庫進行體外篩檢，高效地分離針對各種複雜靶點的結合物。該技術無需免疫即可產生全人源抗體，使其成為製藥公司、生技公司和其他終端用戶應用最廣泛的技術。

分段 3：依抗體類型

單株抗體在全球抗體發現市場中佔最大佔有率，因為它們是一項成熟的技術，已獲得廣泛核准，並且是多種疾病領域治療研發管線的基礎。然而，雙特異性抗體、抗體藥物複合體（ADC）和其他改良型抗體具有更高的療效和全新的作用機制，其快速的研發和臨床成功使得新一代抗體成為成長最快的細分市場。

細分 4：依性質

由於人源抗體具有最高的生物相容性和最低的免疫抗原性風險，因此它們在生物製劑中佔據最大佔有率。基因改造動物模型、噬菌體展示技術和單B細胞技術的進步，使得高效製備全人源抗體成為可能，使其成為安全持久治療的最佳選擇。

細分5：依治療領域

依治療領域分類，腫瘤治療領域佔最大佔有率，抗體已成為癌症治療的基石，眾多單株抗體、雙特異性抗體和抗體藥物複合體（ADC）核准或處於後期研發階段。龐大的未滿足醫療需求、大量的研發投入以及免疫腫瘤學領域對新一代抗體製劑的快速應用，共同支撐著該治療領域的持續主導地位。

細分6：依最終用戶

從終端用戶角度來看，製藥和生物技術公司預計將在2024年佔據大規模市場佔有率，因為它們進行廣泛的內部研發，並擁有專有的發現平台，建立差異化的產品線。這些公司也積極與其他公司合作，加速抗體發現，同時利用授權協議和收購來擴展其治療產品組合。它們雄厚的財力和對推進新一代抗體療法開發的重視，進一步鞏固了主導地位。

細分7：依地區

北美預計將佔據全球抗體發現市場最大的佔有率，這主要得益於大型生物製藥公司的強大實力、先進的研究基礎設施和高額的研發投入。該地區受益於人工智慧驅動的發現平台的早期應用、廣泛的臨床試驗活動以及有利於生物製藥開發和商業化的法律規範。

本報告檢視了全球抗體發現市場，並總結了關鍵趨勢、市場影響因素分析、法律制度、研發管線分析、市場規模趨勢和預測、按各個細分市場、地區/主要國家進行的詳細分析、競爭格局以及主要企業的概況。

目錄

執行摘要

範圍和定義

第1章 市場：產業展望

  • 監管狀態/合規性
    • 美國
    • EU
    • 亞太地區
    • 其他地區
  • 定價分析
    • 依產品
    • 依地區
  • 供應鏈分析
  • 價值鏈分析
  • 專利分析
    • 依國家/地區
    • 依公司
    • 依技術
  • 市場動態
    • 趨勢、促進因素、挑戰和機會：評估當前和未來的影響

第2章 提供區隔

  • 供應類別：摘要
  • 抗體發現市場（依產品）
    • 抗體發現平台和系統
    • 試劑盒和試劑
    • 抗體庫
    • 其他
  • 抗體發現市場（依服務）
    • 抗原設計與製備
    • 熱門製作和篩檢
    • 線索篩選與最佳化
    • 抗體工程與表徵
    • 其他

第3章 技術

  • 技術摘要
  • 噬菌體展示技術
  • 融合瘤技術
  • 單B細胞技術
  • 基因改造動物方法
  • 其他技術

第4章 抗體類型

  • 抗體類型：摘要
  • 單株抗體（mAbs）
  • 多株抗體
  • 新一代抗體
    • 雙特異性抗體
    • 抗體藥物複合體（ADC）
    • 奈米抗體
    • 其他工程抗體

第5章 屬性

  • 屬性：摘要
  • 人類抗體
  • 人源化抗體
  • 嵌合體抗體
  • 小鼠抗體

第6章 治療區

  • 治療領域：摘要
  • 腫瘤性疾病
  • 免疫疾病
  • 感染疾病
  • 心血管疾病
  • 神經系統疾病
  • 其他

第7章 最終用戶

  • 最終用戶：摘要
  • 製藥和生物技術公司
  • 合約研究組織（CRO）
  • 學術研究機構
  • 其他

第8章 區域

  • 區域：摘要
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東和非洲
    • 區域概覽
    • 市場成長促進因素
    • 市場問題
    • 依提供區隔
    • 依技術
    • 依國家/地區

第9章 市場：競爭基準化分析與公司概況

  • 產品映射
  • 管道分析
  • 各公司的主要策略和發展
  • 公司簡介
    • OmniAb Inc.
    • Twist Bioscience Corporation
    • Biocytogen Pharmaceuticals（Beijing）Co., Ltd.
    • WuXi Biologics（Cayman）Inc.
    • Charles River Laboratories International, Inc.
    • Regeneron Pharmaceuticals, Inc.
    • FairJourney Biologics SA
    • Samsung Biologics
    • Genmab A/S
    • Alloy Therapeutics, Inc.

第10章 調查方法

Product Code: BHL3199SA

This report can be delivered within 1 working day.

Global Antibody Discovery Market: Industry Overview

The global antibody discovery market was valued at approximately $11.15 billion in 2025 and is projected to grow $35.35 billion by 2035, at a CAGR of around 12.23%. The global antibody discovery market is rapidly evolving, driven by advancements in engineering technologies, automation, and artificial intelligence. A major trend shaping this growth is the shift toward fully human and humanized antibodies, which improve therapeutic safety, specificity, and efficacy while reducing immunogenicity. Supported by technologies such as phage display, transgenic animal models, and glycoengineering, these formats are transforming treatments for cancer, autoimmune, and infectious diseases. Additionally, the integration of high-throughput screening, next-generation sequencing, and automation has streamlined antibody identification and optimization, significantly shortening development timelines and improving cost efficiency. The increasing reliance on contract research organizations further enhances scalability and accelerates innovation by providing specialized infrastructure and expertise in antibody screening and engineering.

KEY MARKET STATISTICS
Forecast Period2025 - 2035
2025 Evaluation$11.15 Billion
2035 Forecast$35.35 Billion
CAGR12.23%

Additionally, artificial intelligence and machine learning are reshaping the discovery process by enabling predictive modeling, affinity optimization, and rapid sequence design. These tools enhance precision and reduce development costs, supporting the growing demand for precision therapies. Innovations such as bispecific antibodies, antibody-drug conjugates, and single-domain antibodies are broadening therapeutic potential across oncology, immunology, and rare diseases. Despite challenges such as high production costs and competition from alternative modalities such as gene and cell therapies, continued progress in automation, bioinformatics, and process scalability positions the global antibody discovery market for sustained growth and technological maturity in the coming decade.

Global Antibody Discovery Market Lifecycle Stage

The global antibody discovery market is positioned in the growth stage of its lifecycle, characterized by accelerating innovation, expanding adoption across therapeutic areas, and intensifying competition among established companies and emerging players. The market has evolved beyond early-stage scientific exploration into a mature, technology-driven ecosystem where efficiency, automation, and precision increasingly define competitive advantage. This phase is marked by the rapid integration of artificial intelligence and machine learning-enabled discovery platforms, high-throughput screening, and multi-omics integration, which are significantly reducing development timelines and enhancing candidate success rates.

As the market continues to mature, focus is shifting from innovation-driven discovery toward process optimization, clinical validation, and cost efficiency. Competitive dynamics are expected to intensify as new entrants leverage computational biology and synthetic biology approaches to challenge traditional discovery models. Over the next decade, the global antibody discovery market is anticipated to progress toward the early maturity phase, characterized by broader clinical adoption, standardized workflows, and increasing regulatory clarity.

Market Segmentation:

Segmentation 1: By Offering

  • Product
    • Antibody Discovery Platforms & Systems
    • Kits & Reagents
    • Antibody Libraries
    • Others
  • Services
    • Antigen Designing & Preparation
    • Hit Generation & Screening
    • Lead Selection & Optimization
    • Antibody Engineering & Characterization
    • Other Services

Products account for the larger share of the antibody discovery market as they include antibody discovery platforms and systems, kits, reagents, and antibody libraries, among others that are essential, high-value, and recurrently consumed across discovery workflows. While services generate significant revenue, product sales are often bundled into multiple projects, creating a broader revenue base.

Segmentation 2: By Technology

  • Phage Display Technology
  • Hybridoma Technology
  • Single B-Cell Technologies
  • Transgenic Animal-based Methods
  • Other Technologies

Phage display technology accounts for the largest share in the antibody discovery market as it allows the screening of very large antibody libraries in vitro, making it highly efficient for isolating binders against diverse and difficult targets. Its ability to generate fully human antibodies without the need for immunization has made it the most widely used technology by pharmaceutical and biotechnology companies and other end users.

Segmentation 3: By Antibody Type

  • Monoclonal Antibodies
  • Polyclonal Antibodies
  • Next-Generation Antibodies
    • Bispecific Antibodies
    • Antibody-Drug Conjugates
    • Nanobodies
    • Other Engineered Antibodies

Monoclonal antibodies account for the largest share of the global antibody discovery market as they are well-established, widely approved, and form the backbone of therapeutic pipelines across multiple disease areas. However, next-generation antibodies are expected to be the fastest growing segment, driven by the rapid development and clinical success of bispecifics, ADCs, and other engineered formats that offer improved efficacy and novel mechanisms of action.

Segmentation 4: By Nature

  • Human Antibodies
  • Humanized Antibodies
  • Chimeric Antibodies
  • Murine Antibodies

Human antibodies hold the largest share in the antibody discovery market as they offer the highest compatibility and lowest risk of immunogenicity in patients. Advances in transgenic animal models, phage display, and single B-cell technologies have enabled efficient generation of fully human antibodies, making them the preferred choice as a safe and long-lasting therapeutics.

Segmentation 5: By Therapeutic Area

  • Oncological Disorders
  • Immunological Disorders
  • Infectious Diseases
  • Cardiovascular Disorders
  • Neurological Disorders
  • Other Therapeutic Areas

Oncology disorders account for the largest share of the antibody discovery market because antibodies have become a cornerstone of cancer therapy, with numerous monoclonal antibodies, bispecifics, and ADCs approved and in late-stage pipelines. The high unmet need, significant R&D investment, and rapid adoption of next-generation antibody formats in immuno-oncology drive sustained dominance of this therapeutic area.

Segmentation 6: By End User

  • Pharmaceutical and Biotechnology Companies
  • Contract Research Organizations
  • Academic and Research Institutes
  • Others

Based on end-user segmentation, pharmaceutical and biotechnology companies are expected to account for the largest share of the global antibody discovery market in 2024 as they conduct extensive in-house R&D and maintain proprietary discovery platforms to build differentiated pipelines. These companies also actively collaborate with others to accelerate antibody discovery, while leveraging licensing agreements and acquisitions to expand their therapeutic portfolios. Their strong financial capacity and emphasis on advancing next-generation antibody modalities further reinforce their leading role in this market.

Segmentation 7: By Region

  • North America
  • Europe
  • Asia-Pacific
  • Rest-of-the-World

North America is expected to hold the largest share of the global antibody discovery market, driven by the strong presence of major biopharmaceutical companies, advanced research infrastructure, and high R&D investments. The region benefits from early adoption of AI-driven discovery platforms, extensive clinical trial activity, and supportive regulatory frameworks that accelerate biologics development and commercialization.

Demand - Drivers and Limitations

Demand Drivers for the Global Antibody Discovery Market:

  • Advancements in Antibody Engineering for Therapeutic Applications
  • Increasing Prevalence of Chronic Diseases

Limitations for the Global Antibody Discovery Market:

  • Rising Shift toward Alternative Antibody-Based Treatment Modalities
  • High Costs Restrict Widespread Adoption of Antibody Therapies

How can this report add value to an organization?

Product/Innovation: This report enables organizations to identify high-value opportunities in the global antibody discovery market, focusing on innovation-driven growth across discovery platforms, engineering technologies, and therapeutic applications. It guides R&D investment strategies, technology adoption, and pipeline optimization, allowing companies to prioritize initiatives that accelerate lead identification, candidate validation, and antibody optimization.

Growth/Marketing: The report delivers in-depth insights into regional adoption trends, emerging markets, and partnership opportunities, supporting strategic market entry and commercialization planning. It enables companies to identify growth potential across offering, technology, application, and end-user segments. By understanding regional R&D investments, regulatory frameworks, and technology adoption rates, organizations can refine marketing, licensing, and collaboration strategies, maximize visibility, and increase return on investment in a competitive global landscape.

Competitive: This report provides comprehensive company profiling, competitive benchmarking, highlighting strategic collaborations, funding activities, mergers, acquisitions, and technology adoption trends. Stakeholders gain a clear understanding of competitor focus areas, R&D priorities, and market positioning. This intelligence allows organizations to identify gaps, anticipate market shifts, and formulate strategies to differentiate themselves, optimize market entry, and maintain leadership in the antibody discovery ecosystem.

Key Market Players and Competitive Landscape

The global antibody discovery market is characterized by a rapidly evolving and competitive landscape, driven by technological innovation, strategic partnerships, and the growing demand for next-generation therapeutics. The market comprises a mix of well-established biopharmaceutical companies and emerging biotechnology firms specializing in advanced discovery platforms, contract research services, and integrated biologics development as well as contract research organizations. Key players include:

  • OmniAb Inc.
  • Twist Bioscience Corporation
  • Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
  • WuXi Biologics Inc.
  • Charles River Laboratories International, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • FairJourney Biologics S.A.
  • Samsung Biologics
  • Genmab A/S
  • Alloy Therapeutics, Inc.

Competitive benchmarking highlights mergers and acquisitions, funding activities, licensing deals, and collaborations with pharmaceutical organizations, reflecting the growing emphasis on innovation and speed-to-market. Companies are evaluated based on market presence, technological capabilities, strategic initiatives, and product portfolios. Detailed company profiles cover target end users, technological focus areas, and expert analyst perspectives, providing stakeholders with actionable insights into investment opportunities, market positioning, and strategic growth pathways. This intelligence enables organizations to effectively align their R&D and commercialization strategies with emerging market dynamics of the global antibody discovery market.

Table of Contents

Executive Summary

Scope and Definition

1 Market: Industry Outlook

  • 1.1 Regulatory Landscape / Compliance
    • 1.1.1 U.S.
    • 1.1.2 E.U.
      • 1.1.2.1 Germany
      • 1.1.2.2 France
      • 1.1.2.3 Italy
    • 1.1.3 Asia-Pacific
      • 1.1.3.1 China
      • 1.1.3.2 Japan
    • 1.1.4 Rest-of-the-World
      • 1.1.4.1 Brazil
      • 1.1.4.2 U.A.E.
  • 1.2 Pricing Analysis
    • 1.2.1 By Product
    • 1.2.2 By Region
  • 1.3 Supply Chain Analysis
  • 1.4 Value Chain Analysis
  • 1.5 Patent Analysis
    • 1.5.1 By Country
    • 1.5.2 By Company
    • 1.5.3 By Technology
  • 1.6 Market Dynamics
    • 1.6.1 Trends, Drivers, Challenges, and Opportunities: Current and Future Impact Assessment, 2024-2035
    • 1.6.2 Market Trends
      • 1.6.2.1 Shift toward Fully Human and Humanized Antibodies
      • 1.6.2.2 Increasing Reliance on High-Throughput Screening and Automation
      • 1.6.2.3 Growing Role of Contract Research Organizations (CROs)
    • 1.6.3 Market Drivers
      • 1.6.3.1 Advancements in Antibody Engineering for Therapeutic Applications
      • 1.6.3.2 Increasing Prevalence of Chronic Diseases
    • 1.6.4 Market Challenges
      • 1.6.4.1 Rising Shift Toward Alternative Antibody-Based Treatment Modalities
      • 1.6.4.2 High Costs Restrict Widespread Adoption of Antibody Therapies
    • 1.6.5 Market Opportunities
      • 1.6.5.1 Integration of Artificial Intelligence and Machine Learning in Antibody Discovery

2 Offering

  • 2.1 Offering Summary
  • 2.2 Antibody Discovery Market (by Products)
    • 2.2.1 Antibody Discovery Platforms and Systems
    • 2.2.2 Kits and Reagents
    • 2.2.3 Antibody Libraries
    • 2.2.4 Other Products
  • 2.3 Antibody Discovery Market (by Services)
    • 2.3.1 Antigen Designing and Preparation
    • 2.3.2 Hit Generation and Screening
    • 2.3.3 Lead Selection and Optimization
    • 2.3.4 Antibody Engineering and Characterization
    • 2.3.5 Other Services

3 Technology

  • 3.1 Technology Summary
  • 3.2 Phage Display Technology
  • 3.3 Hybridoma Technology
  • 3.4 Single B-Cell Technologies
  • 3.5 Transgenic Animal-Based Methods
  • 3.6 Other Technologies

4 Antibody Type

  • 4.1 Antibody Type Summary
  • 4.2 Monoclonal Antibodies (mAbs)
  • 4.3 Polyclonal Antibodies
  • 4.4 Next-Generation Antibodies
    • 4.4.1 Bispecific Antibodies
    • 4.4.2 Antibody-Drug Conjugates (ADCs)
    • 4.4.3 Nanobodies
    • 4.4.4 Other Engineered Antibodies

5 Nature

  • 5.1 Nature Summary
  • 5.2 Human Antibodies
  • 5.3 Humanized Antibodies
  • 5.4 Chimeric Antibodies
  • 5.5 Murine Antibodies

6 Therapeutic Area

  • 6.1 Therapeutic Area Summary
  • 6.2 Oncological Disorders
  • 6.3 Immunological Disorders
  • 6.4 Infectious Diseases
  • 6.5 Cardiovascular Disorders
  • 6.6 Neurological Disorders
  • 6.7 Other Therapeutic Areas

7 End User

  • 7.1 End User Summary
  • 7.2 Pharmaceutical and Biotechnology Companies
  • 7.3 Contract Research Organizations (CROs)
  • 7.4 Academic and Research Institutes
  • 7.5 Others

8 Region

  • 8.1 Regional Summary
  • 8.2 North America
    • 8.2.1 Regional Overview
    • 8.2.2 Driving Factors for Market Growth
    • 8.2.3 Factors Challenging the Market
    • 8.2.4 By Offering
    • 8.2.5 By Technology
    • 8.2.6 By Country
      • 8.2.6.1 U.S.
        • 8.2.6.1.1 By Offering
        • 8.2.6.1.2 By Technology
      • 8.2.6.2 Canada
        • 8.2.6.2.1 By Offering
        • 8.2.6.2.2 By Technology
  • 8.3 Europe
    • 8.3.1 Regional Overview
    • 8.3.2 Driving Factors for Market Growth
    • 8.3.3 Factors Challenging the Market
    • 8.3.4 By Offering
    • 8.3.5 By Technology
    • 8.3.6 By Country
      • 8.3.6.1 U.K.
        • 8.3.6.1.1 By Offering
        • 8.3.6.1.2 By Technology
      • 8.3.6.2 Germany
        • 8.3.6.2.1 By Offering
        • 8.3.6.2.2 By Technology
      • 8.3.6.3 France
        • 8.3.6.3.1 By Offering
        • 8.3.6.3.2 By Technology
      • 8.3.6.4 Italy
        • 8.3.6.4.1 By Offering
        • 8.3.6.4.2 By Technology
      • 8.3.6.5 Spain
        • 8.3.6.5.1 By Offering
        • 8.3.6.5.2 By Technology
      • 8.3.6.6 Sweden
        • 8.3.6.6.1 By Offering
        • 8.3.6.6.2 By Technology
      • 8.3.6.7 Netherlands
        • 8.3.6.7.1 By Offering
        • 8.3.6.7.2 By Technology
      • 8.3.6.8 Rest-of-Europe
        • 8.3.6.8.1 By Offering
        • 8.3.6.8.2 By Technology
  • 8.4 Asia-Pacific
    • 8.4.1 Regional Overview
    • 8.4.2 Driving Factors for Market Growth
    • 8.4.3 Factors Challenging the Market
    • 8.4.4 By Offering
    • 8.4.5 By Technology
    • 8.4.6 By Country
      • 8.4.6.1 Japan
        • 8.4.6.1.1 By Offering
        • 8.4.6.1.2 By Technology
      • 8.4.6.2 China
        • 8.4.6.2.1 By Offering
        • 8.4.6.2.2 By Technology
      • 8.4.6.3 India
        • 8.4.6.3.1 By Offering
        • 8.4.6.3.2 By Technology
      • 8.4.6.4 Australia
        • 8.4.6.4.1 By Offering
        • 8.4.6.4.2 By Technology
      • 8.4.6.5 South Korea
        • 8.4.6.5.1 By Offering
        • 8.4.6.5.2 By Technology
      • 8.4.6.6 Singapore
        • 8.4.6.6.1 By Offering
        • 8.4.6.6.2 By Technology
      • 8.4.6.7 Rest-of-Asia-Pacific
        • 8.4.6.7.1 By Offering
        • 8.4.6.7.2 By Technology
  • 8.5 Latin America
    • 8.5.1 Regional Overview
    • 8.5.2 Driving Factors for Market Growth
    • 8.5.3 Factors Challenging the Market
    • 8.5.4 By Offering
    • 8.5.5 By Technology
    • 8.5.6 By Country
      • 8.5.6.1 Brazil
        • 8.5.6.1.1 By Offering
        • 8.5.6.1.2 By Technology
      • 8.5.6.2 Mexico
        • 8.5.6.2.1 By Offering
        • 8.5.6.2.2 By Technology
      • 8.5.6.3 Argentina
        • 8.5.6.3.1 By Offering
        • 8.5.6.3.2 By Technology
      • 8.5.6.4 Rest-of-Latin America
        • 8.5.6.4.1 By Offering
        • 8.5.6.4.2 By Technology
  • 8.6 Middle East and Africa
    • 8.6.1 Regional Overview
    • 8.6.2 Driving Factors for Market Growth
    • 8.6.3 Factors Challenging the Market
    • 8.6.4 By Offering
    • 8.6.5 By Technology
    • 8.6.6 By Country
      • 8.6.6.1 K.S.A.
        • 8.6.6.1.1 By Offering
        • 8.6.6.1.2 By Technology
      • 8.6.6.2 U.A.E.
        • 8.6.6.2.1 By Offering
        • 8.6.6.2.2 By Technology
      • 8.6.6.3 Rest of-Middle East and Africa
        • 8.6.6.3.1 By Offering
        • 8.6.6.3.2 By Technology

9 Markets - Competitive Benchmarking & Company Profiles

  • 9.1 Product Mapping
    • 9.1.1 By Company
    • 9.1.2 By Offering
    • 9.1.3 By Technology
  • 9.2 Pipeline Analysis
  • 9.3 Key Strategies and Developments by Company
    • 9.3.1 Funding Activities
    • 9.3.2 Mergers and Acquisitions
    • 9.3.3 Regulatory Approvals and Product Launches
    • 9.3.4 Partnerships, Collaborations, and Business Expansions
  • 9.4 Company Profiles
    • 9.4.1 OmniAb Inc.
      • 9.4.1.1 Overview
      • 9.4.1.2 Top Products/Product Portfolio
      • 9.4.1.3 Top Competitors
      • 9.4.1.4 Target Customers
      • 9.4.1.5 Key Personal
      • 9.4.1.6 Analyst View
    • 9.4.2 Twist Bioscience Corporation
      • 9.4.2.1 Overview
      • 9.4.2.2 Top Products/Product Portfolio
      • 9.4.2.3 Top Competitors
      • 9.4.2.4 Target Customers
      • 9.4.2.5 Key Personal
      • 9.4.2.6 Analyst View
    • 9.4.3 Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
      • 9.4.3.1 Overview
      • 9.4.3.2 Top Products/Product Portfolio
      • 9.4.3.3 Top Competitors
      • 9.4.3.4 Target Customers
      • 9.4.3.5 Key Personal
      • 9.4.3.6 Analyst View
    • 9.4.4 WuXi Biologics (Cayman) Inc.
      • 9.4.4.1 Overview
      • 9.4.4.2 Top Products/Product Portfolio
      • 9.4.4.3 Top Competitors
      • 9.4.4.4 Target Customers
      • 9.4.4.5 Key Personal
      • 9.4.4.6 Analyst View
    • 9.4.5 Charles River Laboratories International, Inc.
      • 9.4.5.1 Overview
      • 9.4.5.2 Top Products/Product Portfolio
      • 9.4.5.3 Top Competitors
      • 9.4.5.4 Target Customers
      • 9.4.5.5 Key Personal
      • 9.4.5.6 Analyst View
    • 9.4.6 Regeneron Pharmaceuticals, Inc.
      • 9.4.6.1 Overview
      • 9.4.6.2 Top Products/Product Portfolio
      • 9.4.6.3 Top Competitors
      • 9.4.6.4 Target Customers
      • 9.4.6.5 Key Personal
      • 9.4.6.6 Analyst View
    • 9.4.7 FairJourney Biologics S.A.
      • 9.4.7.1 Overview
      • 9.4.7.2 Top Products/Product Portfolio
      • 9.4.7.3 Top Competitors
      • 9.4.7.4 Target Customers
      • 9.4.7.5 Key Personal
      • 9.4.7.6 Analyst View
    • 9.4.8 Samsung Biologics
      • 9.4.8.1 Overview
      • 9.4.8.2 Top Products/Product Portfolio
      • 9.4.8.3 Top Competitors
      • 9.4.8.4 Target Customers
      • 9.4.8.5 Key Personal
      • 9.4.8.6 Analyst View
    • 9.4.9 Genmab A/S
      • 9.4.9.1 Overview
      • 9.4.9.2 Top Products/Product Portfolio
      • 9.4.9.3 Top Competitors
      • 9.4.9.4 Target Customers
      • 9.4.9.5 Key Personal
      • 9.4.9.6 Analyst View
    • 9.4.10 Alloy Therapeutics, Inc.
      • 9.4.10.1 Overview
      • 9.4.10.2 Top Products/Product Portfolio
      • 9.4.10.3 Top Competitors
      • 9.4.10.4 Target Customers
      • 9.4.10.5 Key Personal
      • 9.4.10.6 Analyst View

10 Research Methodology

  • 10.1 Data Sources
    • 10.1.1 Primary Data Sources
    • 10.1.2 Secondary Data Sources
    • 10.1.3 Data Triangulation
  • 10.2 Market Estimation and Forecast

List of Figures

  • Figure 1: Global Antibody Discovery Market (by Scenario), $Billion, 2024, 2030, and 2035
  • Figure 2: Global Antibody Discovery Market (by Region), $Billion, 2024 and 2035
  • Figure 3: Global Antibody Discovery Market (by Offering), $Billion, 2024, 2030, and 2035
  • Figure 4: Global Antibody Discovery Market (by Technology), $Billion, 2024, 2030, and 2035
  • Figure 5: Global Antibody Discovery Market (by AntibodyType), $Billion, 2024, 2030, and 2035
  • Figure 6: Global Antibody Discovery Market (by Nature), $Billion, 2024, 2030, and 2035
  • Figure 7: Global Antibody Discovery Market (by Therapeutic Area), $Billion, 2024, 2030, and 2035
  • Figure 8: Global Antibody Discovery Market (by End User), $Billion, 2024, 2030, and 2035
  • Figure 9: Global Antibody Discovery Market, Value Chain Analysis
  • Figure 10: Global Antibody Discovery Market, Patent Analysis (by Country), January 2022- August 2025
  • Figure 11: Global Antibody Discovery Market, Patent Analysis (by Company), January 2022- August 2025
  • Figure 12: Global Antibody Discovery Market, Patent Analysis (by Technology), January 2022- August 2025
  • Figure 13: Global Antibody Discovery Market (by Offering), $Billion, 2024, 2030, and 2035
  • Figure 14: Global Antibody Discovery Market (Antibody Discovery Platforms and Systems), $Billion, 2024-2035
  • Figure 15: Global Antibody Discovery Market (Kits and Reagents), $Billion, 2024-2035
  • Figure 16: Global Antibody Discovery Market (Antibody Libraries), $Billion, 2024-2035
  • Figure 17: Global Antibody Discovery Market (Other Products), $Billion, 2024-2035
  • Figure 18: Global Antibody Discovery Market (Antigen Designing and Preparation), $Billion, 2024-2035
  • Figure 19: Global Antibody Discovery Market (Hit Generation and Screening), $Billion, 2024-2035
  • Figure 20: Global Antibody Discovery Market (Lead Selection and Optimization), $Billion, 2024-2035
  • Figure 21: Global Antibody Discovery Market (Antibody Engineering and Characterization), $Billion, 2024-2035
  • Figure 22: Global Antibody Discovery Market (Other Services), $Billion, 2024-2035
  • Figure 23: Global Antibody Discovery Market (by Technology), $Billion, 2024, 2030, and 2035
  • Figure 24: Global Antibody Discovery Market (Phage Display Technology), $Billion, 2024-2035
  • Figure 25: Global Antibody Discovery Market (Hybridoma Technology), $Billion, 2024-2035
  • Figure 26: Global Antibody Discovery Market (Single B-Cell Technologies), $Billion, 2024-2035
  • Figure 27: Global Antibody Discovery Market (Transgenic Animal-Based Methods), $Billion, 2024-2035
  • Figure 28: Global Antibody Discovery Market (Other Technologies), $Billion, 2024-2035
  • Figure 29: Global Antibody Discovery Market (by Antibody Type), $Billion, 2024, 2030, and 2035
  • Figure 30: Global Antibody Discovery Market (Monoclonal Antibodies (mAbs)), $Billion, 2024-2035
  • Figure 31: Global Antibody Discovery Market (Polyclonal Antibodies), $Billion, 2024-2035
  • Figure 32: Global Antibody Discovery Market (Next-Generation Antibodies), $Billion, 2024-2035
  • Figure 33: Global Antibody Discovery Market (Bispecific Antibodies), $Billion, 2024-2035
  • Figure 34: Global Antibody Discovery Market (Antibody-Drug Conjugates(ADCs)), $Billion, 2024-2035
  • Figure 35: Global Antibody Discovery Market (Nanobodies), $Billion, 2024-2035
  • Figure 36: Global Antibody Discovery Market (Other Engineered Antibodies), $Billion, 2024-2035
  • Figure 37: Global Antibody Discovery Market (by Nature), $Billion, 2024-2035
  • Figure 38: Global Antibody Discovery Market (Human Antibodies), $Billion, 2024-2035
  • Figure 39: Global Antibody Discovery Market (Humanized Antibodies), $Billion, 2024-2035
  • Figure 40: Global Antibody Discovery Market (Chimeric Antibodies), $Billion, 2024-2035
  • Figure 41: Global Antibody Discovery Market (Murine Antibodies), $Billion, 2024-2035
  • Figure 42: Global Antibody Discovery Market (by Therapeutic Area), $Billion, 2024-2035
  • Figure 43: Global Antibody Discovery Market (Oncological Disorders), $Billion, 2024-2035
  • Figure 44: Global Antibody Discovery Market (Immunological Disorders), $Billion, 2024-2035
  • Figure 45: Global Antibody Discovery Market (Infectious Diseases), $Billion, 2024-2035
  • Figure 46: Global Antibody Discovery Market (Cardiovascular Disorders), $Billion, 2024-2035
  • Figure 47: Global Antibody Discovery Market (Neurological Disorders), $Billion, 2024-2035
  • Figure 48: Global Antibody Discovery Market (Other Therapeutic Areas), $Billion, 2024-2035
  • Figure 49: Global Antibody Discovery Market (by End User), $Billion, 2024, 2030, and 2035
  • Figure 50: Global Antibody Discovery Market (Pharmaceutical and Biotechnology Companies), $Billion, 2024-2035
  • Figure 51: Global Antibody Discovery Market (Contract Research Organizations(CROs)), $Billion, 2024-2035
  • Figure 52: Global Antibody Discovery Market (Academic and Research Institutes), $Billion, 2024-2035
  • Figure 53: Global Antibody Discovery Market (Others), $Billion, 2024-2035
  • Figure 54: U.S. Antibody Discovery Market, $Billion, 2024-2035
  • Figure 55: Canada Antibody Discovery Market, $Billion, 2024-2035
  • Figure 56: Europe Antibody Discovery Market, $Billion, 2024-2035
  • Figure 57: U.K. Antibody Discovery Market, $Billion, 2024-2035
  • Figure 58: Germany Antibody Discovery Market, $Billion, 2024-2035
  • Figure 59: France Antibody Discovery Market, $Billion, 2024-2035
  • Figure 60: Italy Antibody Discovery Market, $Billion, 2024-2035
  • Figure 61: Spain Antibody Discovery Market, $Billion, 2024-2035
  • Figure 62: Sweden Antibody Discovery Market, $Billion, 2024-2035
  • Figure 63: nds Antibody Discovery Market, $Billion, 2024-2035
  • Figure 64: Rest-of-Europe Antibody Discovery Market, $Billion, 2024-2035
  • Figure 65: Japan Antibody Discovery Market, $Billion, 2024-2035
  • Figure 66: China Antibody Discovery Market, $Billion, 2024-2035
  • Figure 67: India Antibody Discovery Market, $Billion, 2024-2035
  • Figure 68: Australia Antibody Discovery Market, $Billion, 2024-2035
  • Figure 69: South Korea Antibody Discovery Market, $Billion, 2024-2035
  • Figure 70: Singapore Antibody Discovery Market, $Billion, 2024-2035
  • Figure 71: Rest-of-Asia-Pacific Antibody Discovery Market, $Billion, 2024-2035
  • Figure 72: Brazil Antibody Discovery Market, $Billion, 2024-2035
  • Figure 73: Mexico Antibody Discovery Market, $Billion, 2024-2035
  • Figure 74: Mexico Antibody Discovery Market, $Billion, 2024-2035
  • Figure 75: Rest-of-Latin America Antibody Discovery Market, $Billion, 2024-2035
  • Figure 76: K.S.A. Antibody Discovery Market, $Billion, 2024-2035
  • Figure 77: U.A.E. Antibody Discovery Market, $Billion, 2024-2035
  • Figure 78: Rest-of-Middle East and Africa Antibody Discovery Market, $Billion, 2024-2035
  • Figure 79: Global Antibody Discovery Market, Product Mapping (by Company)
  • Figure 80: Data Triangulation
  • Figure 81: Top-Down and Bottom-Up Approach
  • Figure 82: Assumptions and Limitations

List of Tables

  • Table 1: Market Snapshot
  • Table 2: Pricing Analysis (by Region)
  • Table 3: Antibody Discovery Market (by Region), $Billion, 2024-2035
  • Table 4: North America Antibody Discovery Market (by Offering), $Billion, 2024-2035
  • Table 5: North America Antibody Discovery Market (by Technology), $Billion, 2024-2035
  • Table 6: U.S. Antibody Discovery Market (by Offering), $Billion, 2024-2035
  • Table 7: U.S. Antibody Discovery Market (by Technology), $Billion, 2024-2035
  • Table 8: Canada Antibody Discovery Market (by Offering), $Billion, 2024-2035
  • Table 9: Canada Antibody Discovery Market (by Technology), $Billion, 2024-2035
  • Table 10: Europe Antibody Discovery Market (by Offering), $Billion, 2024-2035
  • Table 11: Europe Antibody Discovery Market (by Technology), $Billion, 2024-2035
  • Table 12: U.K. Antibody Discovery Market (by Offering), $Billion, 2024-2035
  • Table 13: U.K. Antibody Discovery Market (by Technology), $Billion, 2024-2035
  • Table 14: Germany Antibody Discovery Market (by Offering), $Billion, 2024-2035
  • Table 15: Germany Antibody Discovery Market (by Technology), $Billion, 2024-2035
  • Table 16: France Antibody Discovery Market (by Offering), $Billion, 2024-2035
  • Table 17: France Antibody Discovery Market (by Technology), $Billion, 2024-2035
  • Table 18: Italy Antibody Discovery Market (by Offering), $Billion, 2024-2035
  • Table 19: Italy Antibody Discovery Market (by Technology), $Billion, 2024-2035
  • Table 20: Spain Antibody Discovery Market (by Offering), $Billion, 2024-2035
  • Table 21: Spain Antibody Discovery Market (by Technology), $Billion, 2024-2035
  • Table 22: Sweden Antibody Discovery Market (by Offering), $Billion, 2024-2035
  • Table 23: Sweden Antibody Discovery Market (by Technology), $Billion, 2024-2035
  • Table 24: Netherlands Antibody Discovery Market (by Offering), $Billion, 2024-2035
  • Table 25: Netherlands Antibody Discovery Market (by Technology), $Billion, 2024-2035
  • Table 26: Rest-of-Europe Antibody Discovery Market (by Offering), $Billion, 2024-2035
  • Table 27: Rest-of-Europe Antibody Discovery Market (by Technology), $Billion, 2024-2035
  • Table 28: Asia-Pacific Antibody Discovery Market (by Offering), $Billion, 2024-2035
  • Table 29: Asia-Pacific Antibody Discovery Market (by Technology), $Billion, 2024-2035
  • Table 30: Japan Antibody Discovery Market (by Offering), $Billion, 2024-2035
  • Table 31: Japan Antibody Discovery Market (by Technology), $Billion, 2024-2035
  • Table 32: China Antibody Discovery Market (by Offering), $Billion, 2024-2035
  • Table 33: China Antibody Discovery Market (by Technology), $Billion, 2024-2035
  • Table 34: India Antibody Discovery Market (by Offering), $Billion, 2024-2035
  • Table 35: India Antibody Discovery Market (by Technology), $Billion, 2024-2035
  • Table 36: Australia Antibody Discovery Market (by Offering), $Billion, 2024-2035
  • Table 37: Australia Antibody Discovery Market (by Technology), $Billion, 2024-2035
  • Table 38: South Korea Antibody Discovery Market (by Offering), $Billion, 2024-2035
  • Table 39: South Korea Antibody Discovery Market (by Technology), $Billion, 2024-2035
  • Table 40: Singapore Antibody Discovery Market (by Offering), $Billion, 2024-2035
  • Table 41: Singapore Antibody Discovery Market (by Technology), $Billion, 2024-2035
  • Table 42: Rest-of-Asia-Pacific Antibody Discovery Market (by Offering), $Billion, 2024-2035
  • Table 43: Rest-of-Asia-Pacific Antibody Discovery Market (by Technology), $Billion, 2024-2035
  • Table 44: Latin America Antibody Discovery Market (by Offering), $Billion, 2024-2035
  • Table 45: Latin America Antibody Discovery Market (by Technology), $Billion, 2024-2035
  • Table 46: Brazil Antibody Discovery Market (by Offering), $Billion, 2024-2035
  • Table 47: Brazil Antibody Discovery Market (by Technology), $Billion, 2024-2035
  • Table 48: Mexico Antibody Discovery Market (by Offering), $Billion, 2024-2035
  • Table 49: Mexico Antibody Discovery Market (by Technology), $Billion, 2024-2035
  • Table 50: Argentina Antibody Discovery Market (by Offering), $Billion, 2024-2035
  • Table 51: Argentina Antibody Discovery Market (by Technology), $Billion, 2024-2035
  • Table 52: Rest-of-Latin America Antibody Discovery Market (by Offering), $Billion, 2024-2035
  • Table 53: Rest-of-Latin America Antibody Discovery Market (by Technology), $Billion, 2024-2035
  • Table 54: Middle East and Africa Antibody Discovery Market (by Offering), $Billion, 2024-2035
  • Table 55: Middle East and Africa Antibody Discovery Market (by Technology), $Billion, 2024-2035
  • Table 56: K.S.A. Antibody Discovery Market (by Offering), $Billion, 2024-2035
  • Table 57: K.S.A. Antibody Discovery Market (by Technology), $Billion, 2024-2035
  • Table 58: U.A.E. Antibody Discovery Market (by Offering), $Billion, 2024-2035
  • Table 59: U.A.E. Antibody Discovery Market (by Technology), $Billion, 2024-2035
  • Table 60: Rest-of-Middle East and Africa Antibody Discovery Market (by Offering), $Billion, 2024-2035
  • Table 61: Rest-of-Middle East and Africa Antibody Discovery Market (by Technology), $Billion, 2024-2035
  • Table 62: Global Antibody Discovery Market, Product Mapping (by Offering)
  • Table 63: Global Antibody Discovery Market
  • Table 64: Pipeline Analysis